Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir

REFERENCES

• Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997; 94:13193–13197.
   PubMed Web of Science ®Google Scholar
• Finzi D, Hermankova M, Pierson T, et al. Identifi cation of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300.
   PubMed Web of Science ®Google Scholar
• Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA. 1998;95:8869–8873.
   PubMed Web of Science ®Google Scholar
• Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy. Nat Med. 1999;5:512–517.
   PubMed Web of Science ®Google Scholar
• Sheridan PL, Mayall TP, Verdin E, Jones KA. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev. 1997;11:3327–3340.
   PubMed Web of Science ®Google Scholar
• Benkirane M, Chun RF, Xiao H, et al. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem. 1998;273:24898–24905.
   PubMed Web of Science ®Google Scholar
• Ylisastigui L, Coull JJ, Rucker VC, et al. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis. 2004;190:1429–1437.
   PubMed Web of Science ®Google Scholar
• Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366:549–555.
   PubMed Web of Science ®Google Scholar
• Archin NA, Eron JJ, Palmer S, et al. Standard ART and valproic acid have limited impact on the persistence of HIV infection in resting CD4+ T cells. AIDS. 2008;22:1131–1135.
   PubMed Web of Science ®Google Scholar
• Sagot-Lerolle N, Lamine A, Chaix ML et al. Prolonged valproic acid treatment does not reduce the size of the latent HIV reservoir. AIDS. 2008;22:1125–1129.
   PubMed Web of Science ®Google Scholar
• Routy JP, Tremblay CL, Angel JB, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012;13(5):291–296.
   PubMed Web of Science ®Google Scholar
• Louis TA, Lavori PW, Bailar JC, Polansky M. Crossover and self-controlled designs in clinical research. New Engl J Med. 1984;310(1):24–31.
   PubMed Web of Science ®Google Scholar
• Young JM, Florkowski CM, Molyneux SL, et al. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q(10) therapy in hypertensive patients with the metabolic syndrome. Am J Hypertension. 2011;25(2):261–270.
   PubMed Web of Science ®Google Scholar
• Dashti-Khavidaki S, Chamani N, Khalili H, et al. Comparing effects of clonazopam and zolpidem on sleep quality of patients on maintenance hemodialysis. Iran J Kidney Dis. 2011;5(6):404–409.
   PubMed Web of Science ®Google Scholar
• Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steadystate pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. Clin Pharmacol. 2012;52(6):922–931.
   Google Scholar
• Innes S, Norman J, Smith P, et al. Bioequivalence of dispersed stavudine: opened versus closed capsule dosing. Antivir Ther. 2011;16(7):1131–1134.
   PubMed Web of Science ®Google Scholar
• Johnston C, Saracino M, Kuntz S, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomized, open-label, cross-over trials. Lancet. 2012;379 (9816):641–647.
   PubMed Web of Science ®Google Scholar
• Mugwanya K, Baeten JM, Mugo NR. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis. 2011;204(12):1912–1917.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS. 2011;25(12):1481–1487.
   PubMed Web of Science ®Google Scholar
• Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confi rm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727–728.
   PubMed Web of Science ®Google Scholar
• Jones B, Kenward MG, eds. Design and Analysis of Cross-Over Trials (chap. 2). London: Chapman and Hall; 1989.
   Google Scholar
• Woods JR, Williams JG, Tavel M. The two-period crossover design in medical research. Ann Intern Med. 1989;110(7):560–566.
   PubMed Web of Science ®Google Scholar
• Emery S, Capra WB, Cooper DA, et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodefi ciency virus type 1 disease. J Infect Dis. 2000;182:428–434.
   PubMed Web of Science ®Google Scholar
• Dybul M, Hidalgo B, Chun TW, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodefi ciency virus (HIV)-specifi c immune responses in patients treated during recently acquired HIV infection. J Infect Dis. 2002;185:61–68.
   PubMed Web of Science ®Google Scholar
• Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979;8:7–20.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Søgaard O, Melchjorsen J, et al. The histone deacetylase inhibitor (HDACi) panobinostat (LBH589) stimulates HIV-1 expression more potently than other HDACi in clinical use and disrupts HIV latency at clinically achievable concentrations (Paper 370). Presented at: the 20th Conference on Retroviruses and Opportunistic Infections; March 5–8, 2012; Seattle, Washington.
   Google Scholar